CA-VAULTREE
More than 4,100 publicly disclosed data breaches occurred in 2022, with approximately 22 billion records leaked. Most of it was not encrypted. Vaultree, the Data-In-Use Encryption leader, today announced the general availability of a first-of-its-kind software development kit (SDK) to address this massive need.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230315005361/en/
Vaultree's first-of-its-kind Fully Functional Data-In-Use Encryption toolkit will transform enterprise security. (Graphic: Business Wire)
Made possible by a series of major cryptographic breakthroughs by the Vaultree team, the SDK is a user-friendly, simple-to-integrate, and easy-to-use fully scalable solution that enables organizations to benefit from Fully Functional Data-In-Use Encryption, allowing for the processing of fully encrypted data without server-side decryption and complex intermediaries or noticeable delays in data processing.
Vaultree developed the solution to address the problems associated with processing completely encrypted data at scale, ensuring that companies no longer need to sacrifice security for performance and are able to keep their data safe at all times with unmatched simplicity and exceptional encrypted data processing rates. Businesses can retain their tech stack, database, code and SQL syntax, follow the rules, and operate without any perceptible changes, with the added benefit of being completely encrypted and at scale. Vaultree's SDK provides protection, including adherence, security and effectiveness. So, in the event of a leak, rather than issuing an apology about the wholesale exposure of sensitive data, companies will be able to inform clients that although their data has been compromised, it is encrypted, meaning it is protected by encryption, an unparalleled level of security.
This layer of protection also makes CISOs' lives easier by solving one of the most difficult challenges in cybersecurity: persistent data encryption, even in the event of a leak, with the world's first Fully Functional Data-In-Use Encryption solution. Encryption technologies to date have not been able to process encrypted data, decrypting it to plain text for processing and therefore impacting organizations' overall data security, making their data readily available to cyber criminals. Vaultree's encryption solution is smarter, quicker, easier, and more efficient than anything else on the market. Truly zero-trust, it allows users to work with fully encrypted data without key disclosure or server-side decryption. Data-In-Use Encryption maintains data encrypted at all times, even during processing. As an added benefit, there are no intermediaries, which translates to zero learning curve or implementation overhead, making adoption seamless.
Ease of integration and use is another critical differentiator of Vaultree's SDK encryption solution. There is no need to be a cryptographer, no intermediaries (such as APIs, proxies or plugins), no change of data architecture, and no code or SQL syntax change. This remarkable adaptability has made the product a prime mover in the market.
"Vaultree's groundbreaking solution is the first of its kind and will change the encryption landscape as we know it. Data security is not only one of today's hot topics but also the topic of tomorrow. Vaultree is leading the way to a safer future," said Rinki Sethi, member of Vaultree's executive board of directors.
Vaultree's SDK encryption solution tackles the drawbacks of both conventional and contemporary encryption methods with a variety of features, including:
- Close to plaintext processing speed, even at scale
- Keys reside with the client
- End-to-end encrypted in use, decrypted only client-side
- No changes to stack, SQL syntax, data structure, architecture, and network topology
- Complex processing from fulltext search to computations on randomized encrypted data
- Performance and scalability at enterprise levels
- No need for special purpose hardware
Peak performance processing on fully encrypted data enables enterprises to scale to billions of datasets while processing data at speeds similar to unencrypted data processing. Enterprises handling large amounts of sensitive data, including those in financial services, healthcare, pharmaceutical, insurance, retail, telecom, and energy sectors, will be able to mitigate the tremendous economic, cyber, legal, reputational, and business risk of a data breach in plain text — because of the data being encrypted.
"Breaches or leaks will continue happening, no matter how many tools are in the first line of defense, but the second line of defense — encryption — has been neglected for decades because data still has to be decrypted to be worked with. The only way forward is an always-encrypted approach," said Tilo Weigandt, Co-Founder and COO of Vaultree.
Amongst other developments, Vaultree is the first and only (Data-In-Use) encryption solution vendor to partner with Google's AlloyDB for PostgreSQL, leading a new era with a fully functional encryption solution in the cloud. To further expand usage of its revolutionary data protection solution, Vaultree has also partnered with Qrypt. The partnership leverages Qrypt’s ability to independently generate identical symmetric keys at multiple endpoints and quantum-secure future-safe one-time pad encryption paired with Vaultree’s Fully Functional Data-In-Use Encryption to enable fast, future secure data processing in a cloud-first world.
"As it stands, we are the only company globally with the capacity and innovation we have. We are going to grow significantly over the next year enabling organizations with our Data-In-Use encryption technology. We are focusing heavily on bringing this to market fast with our target markets being North America and Europe," said Ryan Lasmaili, Co-Founder and CEO of Vaultree.
About Vaultree
Vaultree has developed the world's first Fully Functional Data-in-Use Encryption solution that solves the industry's fundamental security issue: persistent data encryption, even in the event of a leak. Vaultree enables enterprises, including those in the financial services and healthcare / pharmaceutical sectors, to mitigate the great financial, cyber, legal, reputational, and business risk of a data breach in plain text. With Vaultree, organizations process, search and compute ubiquitous data at scale without ever having to surrender encryption keys or decrypt server-side. If a leak occurs, Vaultree's data-in-use encryption persists, rendering the data unusable to bad actors. Integrating Vaultree into existing database technologies is seamless, requiring no technology or platform changes. Vaultree is a privately held company based in Ireland and the U.S. For more information, please visit www.vaultree.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005361/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 09:05:00 CET | Press release
Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio
SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 09:00:00 CET | Press release
Appointment of industry veteran follows majority growth investment from Bregal Milestone SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive lon
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
